Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar Mar-2015 Mar-2014 Mar-2013 Mar-2012
Growth matrix (%)        
Revenue growth (47) 5.44 36.60 --
Op profit growth (177) 1.60 20.60 --
EBIT growth 42.40 (9.10) 25 --
Net profit growth 340 (65) 115 --
Profitability ratios (%)        
OPM (18) 12.30 12.80 14.50
EBIT margin 22.90 8.47 9.83 10.70
Net profit margin 6.32 0.76 2.25 1.43
RoCE (29) 78.10 45.40 --
RoNW 2.20 0.51 1.51 --
RoA 0.94 0.20 0.60 --
Per share ratios ()        
EPS 3.33 0.77 2.05 1.04
Dividend per share -- -- 0.60 --
Cash EPS 0.10 (4.10) (2.30) (2.40)
Book value per share 38.50 36.90 36.20 34.70
Valuation ratios        
P/E 0.77 0.46 1.06 1.36
P/CEPS 289 (4.20) (17) (19)
P/B 0.77 0.46 1.06 1.36
EV/EBIDTA 4.28 5.55 5.90 8.42
Payout (%)        
Dividend payout -- -- 32.80 --
Tax payout 1.71 (42) (28) (63)
Liquidity ratios        
Debtor days 348 186 182 --
Inventory days 81.30 48.80 47.90 --
Creditor days (133) (135) (163) --
Leverage ratios        
Interest coverage (1.70) (1.20) (1.40) (1.70)
Net debt / equity 0.92 1.53 1.17 1.30
Net debt / op. profit (3.70) 4.61 3.52 4.45
Cost breakup ()        
Material costs (84) (70) (73) (73)
Employee costs (11) (7.70) (6.20) (4.60)
Other costs (23) (10) (7.80) (8.20)
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar( In .Cr) Mar-2015 Mar-2014 Mar-2013 Mar-2012
Revenue 97.70 185 176 129
yoy growth (%) (47) 5.44 36.60 --
Raw materials (82) (130) (129) (94)
As % of sales 83.60 69.90 73.20 72.80
Employee costs (11) (14) (11) (5.90)
As % of sales 11 7.68 6.21 4.55
Other costs (23) (19) (14) (11)
As % of sales 23.40 10.10 7.82 8.17
Operating profit (18) 22.80 22.50 18.60
OPM (18) 12.30 12.80 14.50
Depreciation (6) (9) (8.20) (6.30)
Interest expense (13) (13) (12) (8.30)
Other income 46 1.85 3.04 1.48
Profit before tax 8.90 2.49 5.36 5.50
Taxes 0.15 (1) (1.50) (3.50)
Tax rate 1.71 (42) (28) (63)
Minorities and other -- -- (0.10) (0.10)
Adj. profit 9.01 1.40 3.83 1.97
Exceptional items (2.80) -- 0.13 (0.10)
Net profit 6.18 1.40 3.96 1.84
yoy growth (%) 340 (65) 115 --
NPM 6.32 0.76 2.25 1.43
Switch to
Tabular Data
Graph
Y/e 31 Mar ( In .Cr) Mar-2015 Mar-2014 Mar-2013 Mar-2012
Profit before tax 8.90 2.49 5.36 5.50
Depreciation (6) (9) (8.20) (6.30)
Tax paid 0.15 (1) (1.50) (3.50)
Working capital (0.90) 12.80 (13) --
Other operating items -- -- -- --
Operating cashflow 2.13 5.24 (17) --
Capital expenditure (11) 4.63 (4.60) --
Free cash flow (8.90) 9.87 (22) --
Equity raised 92.70 97.60 96.20 --
Investments 16.90 -- -- --
Debt financing/disposal (17) 8.04 (8) --
Dividends paid -- -- 1.12 --
Other items -- -- -- --
Net in cash 83.90 116 67.40 --
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar ( In .Cr) Mar-2015 Mar-2014 Mar-2013 Mar-2012
Equity capital 18.70 18.70 21.80 24.30
Preference capital -- -- -- --
Reserves 53.10 50.20 45.70 39.60
Net worth 71.80 68.90 67.50 63.80
Minority interest
Debt 68.70 108 100 85.40
Deferred tax liabilities (net) 4 6.41 5.83 5.25
Total liabilities 145 184 174 155
Fixed assets 54.60 69.30 73 76.20
Intangible assets
Investments 16.90 -- -- --
Deferred tax asset (net) -- -- -- --
Net working capital 71.10 112 80.30 76.60
Inventories 16.10 27.40 22.20 23.90
Inventory Days 60.20 54 46.10 67.90
Sundry debtors 88.70 97.50 91.60 83.90
Debtor days 331 192 190 238
Other current assets 20.80 38.80 52.70 32.50
Sundry creditors (42) (42) (79) (58)
Creditor days 158 82.40 163 166
Other current liabilities (12) (9.60) (7.60) (5.30)
Cash 2.77 2.81 21.10 2.46
Total assets 145 184 174 155
Switch to
Consolidated
Standalone


Bafna Pharmaceuticals Ltd Report not showing data